BMY

Bristol-Myers Squibb
D

BMY

Arincen68/100B

Bristol-Myers Squibb balance sheet 1987–2026

Bristol-Myers Squibb had 12.58B USD in cash and short-term investments on 30 September 2026, against total debt of 44.81B USD: net debt of 32.23B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
9.57B10.21B10.35B11.46B9.12B13.98B14.55B12.35B6.91B5.42B4.24B
Short-term investments
3.01B464.00M513.00M816.00M130.00M3.24B1.90B3.05B1.85B1.39B2.11B
12.58B10.67B10.86B12.28B9.25B17.22B16.45B15.39B8.76B6.81B6.35B
Cash growth
-23.76%-1.71%-11.57%+32.71%-46.27%+4.69%+6.87%+75.74%+28.58%+7.28%+48.71%
Receivables
10.64B14.53B14.42B15.26B13.94B12.52B10.55B7.69B5.75B6.30B5.54B
Inventory
2.70B2.69B2.56B2.66B2.34B2.10B2.07B4.29B1.20B1.17B1.24B
Other current assets
3.84B1.50B1.94B1.56B1.74B1.43B-685.00M1.23B899.00M0.000.00
Total current assets
29.77B29.39B29.78B31.77B27.27B33.26B30.19B29.35B17.72B14.85B13.70B
Property, plant and equipment
7.97B9.13B8.36B8.04B7.48B6.97B6.75B6.96B5.03B5.00B4.98B
Long-term investments
378.00M2.51B2.51B2.50B2.19B2.71B4.51B4.17B1.78B2.48B2.72B
Goodwill and intangibles
38.67B40.86B45.36B48.65B57.50B63.28B74.00B86.46B7.63B8.07B8.26B
Goodwill
21.74B21.75B21.72B21.17B21.15B20.50B20.55B22.49B6.54B6.86B6.88B
Intangible assets
16.94B19.10B23.64B27.49B36.36B42.78B53.45B63.97B1.09B1.21B1.39B
Other non-current assets
6.10B2.78B2.36B1.43B1.04B1.66B1.88B2.50B2.02B1.53B1.05B
Total assets
88.77B90.04B92.60B95.16B96.82B109.31B118.48B129.94B34.99B33.55B33.71B
Accounts payable
4.63B3.58B3.60B3.26B3.04B2.95B2.71B2.45B1.89B2.25B1.66B
Deferred revenue
0.000.000.000.000.000.000.000.00172.00M83.00M762.00M
Short-term debt
1.25B2.26B2.05B3.12B4.26B4.95B2.34B3.35B1.70B987.00M992.00M
Other current liabilities
12.88B14.63B14.60B12.79B11.99B11.48B11.65B9.35B5.75B909.00M862.00M
Total current liabilities
18.75B23.42B23.77B22.26B21.89B21.87B19.08B18.30B10.65B9.56B8.84B
Long-term debt
41.85B42.85B47.60B36.65B35.06B39.61B48.34B43.39B5.65B6.98B5.72B
Other non-current liabilities
2.70B3.05B2.87B4.59B5.05B6.13B6.59B9.01B4.07B4.71B2.26B
Lease obligations, current
0.00202.00M181.00M162.00M136.00M169.00M164.00M133.00M0.000.000.00
Lease obligations, long-term
1.71B1.83B1.37B1.53B1.26B874.00M833.00M672.00M0.000.000.00
Total liabilities
65.37B71.53B76.22B65.67B65.70B73.31B80.60B78.25B20.86B21.70B17.36B
Common stock and paid-in capital
292.00M292.00M292.00M292.00M292.00M292.00M292.00M292.00M221.00M221.00M221.00M
Retained earnings
21.19B16.90B14.91B28.77B25.50B23.82B21.28B34.47B34.07B31.16B33.51B
Accumulated other comprehensive income
-1.28B-1.52B-1.24B-1.55B-1.28B-1.27B-1.84B-1.52B-2.76B-2.29B-2.50B
Shareholders' equity
23.40B18.47B16.34B29.43B31.06B35.95B37.82B51.60B14.03B11.74B16.18B
Minority interest
0.0033.00M53.00M55.00M57.00M60.00M60.00M100.00M96.00M106.00M170.00M
44.81B47.14B51.20B41.46B40.72B45.60B51.67B47.54B7.35B7.96B6.71B
Net cash
-32.23B-36.47B-40.34B-29.18B-31.46B-28.38B-35.22B-32.15B1.41B-1.15B-358.00M
Working capital
11.01B5.97B6.01B9.51B5.38B11.39B11.11B11.05B7.06B5.29B4.86B
Book value per share
11.409.058.0614.1614.4716.0116.7530.148.577.119.63
Tangible book value
-15.27B-22.38B-29.03B-19.22B-26.44B-27.33B-36.17B-34.86B6.40B3.67B7.92B
Tangible book value per share
-7.44-10.97-14.32-9.25-12.32-12.17-16.02-20.363.912.224.71
Current ratio
1.591.261.251.431.251.521.581.601.661.551.55
Debt to equity
1.912.553.131.411.311.271.370.920.520.680.41

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Bristol-Myers Squibb's cash and debt

Source: Financial Modeling PrepVerified against SEC filings